Company intelligence / Profile preview
Cullgen Inc.
San Diego, California, United Statescullgen.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Currently in Phase 1 dosing of CG001419, an oral pan-TRK protein degrader for acute and chronic pain. The company has also received Chinese NMPA allowance for an investigational new drug application for CG009301, a selective GSPT1 degrader.
- Therapeutic areas
- OncologyImmunologyNeurology
- Modalities
- Small moleculestargeted protein degradersdegrader-antibody conjugates (DACs)
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
03
Partnerships
Astellas PharmaAstraZeneca-CICC Venture Capital PartnershipPulmatrix (proposed merger)
Beyond the preview
Go deeper on Cullgen Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cullgen Inc..